This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): rhuMAb-VEGF, anti-VEGF, R435, RG435, RO4876646
Description: Avastin is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF). Inhibiting VEGF protein function leads to diminished blood vessel formation such that tumors tend to be deprived of nourishing blood flow needed for their growth and metastasis. On the other hand, VEGF inhibition has been associated with adversities of both clotting and bleeding related to its actions at the level of blood vessel channel-lining cells.
Revenue splits for this drug are BioMedTracker estimates.
Roche & Genentech
In June 2003, Hoffmann-La Roche exercised its option to license from Genentech the rights to market Avastin for all countries outside of the U.S. under its existing licensing agreement with Genentech. As part of its opt-in, Hoffmann-La Roche paid Genentech approximately $188.0 million and will pay 75% of subsequent Avastin global development costs unless Hoffmann-La Roche specifically opts out of the development of certain other indications. Genentech will receive royalties on net sales of Avastin in countries outside of the U.S.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009....See full deal structure in Biomedtracker
Partners: PDL BioPharma, Inc. Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: